IMAC (IMAC) Competitors

$0.04 0.00 (0.00%)

As of 05/1/2026

IMAC vs. SYRA, CLGN, DRMA, PPBT, and CDIO

Should you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Syra Health (SYRA), CollPlant Biotechnologies (CLGN), Dermata Therapeutics (DRMA), Purple Biotech (PPBT), and Cardio Diagnostics (CDIO). These companies are all part of the "medical" sector.

How does IMAC compare to Syra Health?

Syra Health (NASDAQ:SYRA) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

: 4.8% of Syra Health shares are held by institutional investors. Comparatively, 24.3% of IMAC shares are held by institutional investors. 24.6% of Syra Health shares are held by insiders. Comparatively, 10.0% of IMAC shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Syra Health has a net margin of -54.90% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Syra Health's return on equity.
Company Net Margins Return on Equity Return on Assets
Syra Health -54.90% -131.94% -99.19%
IMAC -75.40% -52.17% -34.51%
: In the previous week, IMAC had 5 more articles in the media than Syra Health. MarketBeat recorded 6 mentions for IMAC and 1 mentions for Syra Health. IMAC's average media sentiment score of 0.42 beat Syra Health's score of 0.00 indicating that IMAC is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Syra Health
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
IMAC
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Syra Health has a beta of 3.1, indicating that its share price is 210% more volatile than the S&P 500. Comparatively, IMAC has a beta of -0.88, indicating that its share price is 188% less volatile than the S&P 500.
: Syra Health has higher earnings, but lower revenue than IMAC. Syra Health is trading at a lower price-to-earnings ratio than IMAC, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Syra Health $7.98M 0.64 -$2.94M -$0.08 N/A
IMAC $15.22M 0.07 -$10.54M -$0.27 N/A

Company	Net Margins	Return on Equity	Return on Assets
Syra Health	-54.90%	-131.94%	-99.19%
IMAC	-75.40%	-52.17%	-34.51%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syra Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IMAC	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syra Health	$7.98M	0.64	-$2.94M	-$0.08	N/A
IMAC	$15.22M	0.07	-$10.54M	-$0.27	N/A

Summary

IMAC beats Syra Health on 7 of the 13 factors compared between the two stocks.

How does IMAC compare to CollPlant Biotechnologies?

CollPlant Biotechnologies (NASDAQ:CLGN) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

: IMAC has higher revenue and earnings than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than IMAC, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CollPlant Biotechnologies $2.37M 2.44 -$11.49M -$1.35 N/A
IMAC $15.22M 0.07 -$10.54M -$0.27 N/A
: IMAC has a net margin of -75.40% compared to CollPlant Biotechnologies' net margin of -353.70%. IMAC's return on equity of -52.17% beat CollPlant Biotechnologies' return on equity.
Company Net Margins Return on Equity Return on Assets
CollPlant Biotechnologies -353.70% -161.69% -109.44%
IMAC -75.40% -52.17% -34.51%
: 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 24.3% of IMAC shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Comparatively, 10.0% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: In the previous week, IMAC had 6 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 6 mentions for IMAC and 0 mentions for CollPlant Biotechnologies. IMAC's average media sentiment score of 0.42 beat CollPlant Biotechnologies' score of 0.00 indicating that IMAC is being referred to more favorably in the news media.
Company Overall Sentiment
CollPlant Biotechnologies Neutral
IMAC Neutral
: CollPlant Biotechnologies has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, IMAC has a beta of -0.88, indicating that its stock price is 188% less volatile than the S&P 500.
: CollPlant Biotechnologies currently has a consensus target price of $11.50, suggesting a potential upside of 2,760.70%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe CollPlant Biotechnologies is more favorable than IMAC.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CollPlant Biotechnologies
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
IMAC
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.44	-$11.49M	-$1.35	N/A
IMAC	$15.22M	0.07	-$10.54M	-$0.27	N/A

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-353.70%	-161.69%	-109.44%
IMAC	-75.40%	-52.17%	-34.51%

Company	Overall Sentiment
CollPlant Biotechnologies	Neutral
IMAC	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

IMAC beats CollPlant Biotechnologies on 11 of the 16 factors compared between the two stocks.

How does IMAC compare to Dermata Therapeutics?

Dermata Therapeutics (NASDAQ:DRMA) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

: 8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 24.3% of IMAC shares are owned by institutional investors. 21.9% of Dermata Therapeutics shares are owned by company insiders. Comparatively, 10.0% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: In the previous week, IMAC had 6 more articles in the media than Dermata Therapeutics. MarketBeat recorded 6 mentions for IMAC and 0 mentions for Dermata Therapeutics. IMAC's average media sentiment score of 0.42 beat Dermata Therapeutics' score of 0.00 indicating that IMAC is being referred to more favorably in the news media.
Company Overall Sentiment
Dermata Therapeutics Neutral
IMAC Neutral
: Dermata Therapeutics has higher earnings, but lower revenue than IMAC. IMAC is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dermata Therapeutics N/A N/A -$7.56M -$9.33 N/A
IMAC $15.22M 0.07 -$10.54M -$0.27 N/A
: Dermata Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 688.64%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Dermata Therapeutics is more favorable than IMAC.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dermata Therapeutics
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
IMAC
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Dermata Therapeutics has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Dermata Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Dermata Therapeutics N/A -130.89% -102.20%
IMAC -75.40% -52.17% -34.51%
: Dermata Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, IMAC has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
IMAC	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$9.33	N/A
IMAC	$15.22M	0.07	-$10.54M	-$0.27	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-130.89%	-102.20%
IMAC	-75.40%	-52.17%	-34.51%

Summary

Dermata Therapeutics beats IMAC on 8 of the 15 factors compared between the two stocks.

How does IMAC compare to Purple Biotech?

IMAC (NASDAQ:IMAC) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

: 24.3% of IMAC shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 10.0% of IMAC shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: In the previous week, IMAC had 6 more articles in the media than Purple Biotech. MarketBeat recorded 6 mentions for IMAC and 0 mentions for Purple Biotech. IMAC's average media sentiment score of 0.42 beat Purple Biotech's score of 0.00 indicating that IMAC is being referred to more favorably in the media.
Company Overall Sentiment
IMAC Neutral
Purple Biotech Neutral
: IMAC has higher revenue and earnings than Purple Biotech. Purple Biotech is trading at a lower price-to-earnings ratio than IMAC, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IMAC $15.22M 0.07 -$10.54M -$0.27 N/A
Purple Biotech N/A N/A -$26.39M -$20.45 N/A
: Purple Biotech has a consensus target price of $30.00, suggesting a potential upside of 614.29%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than IMAC.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IMAC
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Purple Biotech
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Purple Biotech has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Purple Biotech's return on equity.
Company Net Margins Return on Equity Return on Assets
IMAC -75.40% -52.17% -34.51%
Purple Biotech N/A -98.44% -83.37%
: IMAC has a beta of -0.88, suggesting that its stock price is 188% less volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.

Company	Overall Sentiment
IMAC	Neutral
Purple Biotech	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMAC	$15.22M	0.07	-$10.54M	-$0.27	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$20.45	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
IMAC	-75.40%	-52.17%	-34.51%
Purple Biotech	N/A	-98.44%	-83.37%

Summary

IMAC beats Purple Biotech on 10 of the 15 factors compared between the two stocks.

How does IMAC compare to Cardio Diagnostics?

IMAC (NASDAQ:IMAC) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

: IMAC has a net margin of -75.40% compared to Cardio Diagnostics' net margin of -40,612.50%. IMAC's return on equity of -52.17% beat Cardio Diagnostics' return on equity.
Company Net Margins Return on Equity Return on Assets
IMAC -75.40% -52.17% -34.51%
Cardio Diagnostics -40,612.50% -71.75% -66.25%
: In the previous week, IMAC had 4 more articles in the media than Cardio Diagnostics. MarketBeat recorded 6 mentions for IMAC and 2 mentions for Cardio Diagnostics. IMAC's average media sentiment score of 0.42 beat Cardio Diagnostics' score of 0.12 indicating that IMAC is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IMAC
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cardio Diagnostics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 24.3% of IMAC shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 10.0% of IMAC shares are held by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Cardio Diagnostics has lower revenue, but higher earnings than IMAC. Cardio Diagnostics is trading at a lower price-to-earnings ratio than IMAC, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IMAC $15.22M 0.07 -$10.54M -$0.27 N/A
Cardio Diagnostics $10K 546.12 -$6.50M -$3.72 N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IMAC
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Cardio Diagnostics
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: IMAC has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
IMAC	-75.40%	-52.17%	-34.51%
Cardio Diagnostics	-40,612.50%	-71.75%	-66.25%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IMAC	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardio Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMAC	$15.22M	0.07	-$10.54M	-$0.27	N/A
Cardio Diagnostics	$10K	546.12	-$6.50M	-$3.72	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

IMAC beats Cardio Diagnostics on 9 of the 14 factors compared between the two stocks.

Get IMAC News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMAC vs. The Competition

Export

Metric	IMAC	Specialty Outpatient Clinics Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.14M	$972K	$6.28B	$12.08B
Dividend Yield	N/A	N/A	2.74%	5.26%
P/E Ratio	-0.16	N/A	29.20	27.30
Price / Sales	0.07	0.07	491.35	76.15
Price / Cash	N/A	N/A	43.30	53.90
Price / Book	0.06	0.06	9.75	6.73
Net Income	-$10.54M	-$10.54M	$3.55B	$332.77M
7 Day Performance	N/A	N/A	3.75%	3.98%
1 Month Performance	N/A	N/A	5.81%	8.78%
1 Year Performance	N/A	N/A	40.01%	43.14%

IMAC Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMAC IMAC	N/A	$0.04 flat	N/A	+18.5%	$1.14M	$15.22M	N/A	106	News Coverage
SYRA Syra Health	N/A	$0.49 -5.8%	N/A	+346.6%	$5.56M	$7.98M	N/A	78	Upcoming Earnings Gap Up
CLGN CollPlant Biotechnologies	1.4538 of 5 stars	$0.38 +2.8%	$11.50 +2,903.4%	-80.9%	$5.52M	$2.37M	N/A	70	Positive News Gap Down
DRMA Dermata Therapeutics	3.2874 of 5 stars	$1.37 +8.7%	$10.00 +629.9%	-84.8%	$5.51M	N/A	N/A	8	Positive News Analyst Downgrade
PPBT Purple Biotech	3.2881 of 5 stars	$4.13 -2.4%	$30.00 +626.4%	-82.9%	$5.31M	N/A	N/A	20	Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMAC) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IMAC (IMAC) Competitors

IMAC vs. SYRA, CLGN, DRMA, PPBT, and CDIO

How does IMAC compare to Syra Health?

Summary

How does IMAC compare to CollPlant Biotechnologies?

Summary

How does IMAC compare to Dermata Therapeutics?

Summary

How does IMAC compare to Purple Biotech?

Summary

How does IMAC compare to Cardio Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMAC vs. The Competition

IMAC Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IMAC (IMAC) Competitors

IMAC vs. SYRA, CLGN, DRMA, PPBT, and CDIO

How does IMAC compare to Syra Health?

Summary

How does IMAC compare to CollPlant Biotechnologies?

Summary

How does IMAC compare to Dermata Therapeutics?

Summary

How does IMAC compare to Purple Biotech?

Summary

How does IMAC compare to Cardio Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMAC vs. The Competition

IMAC Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools